1 emerging growth stock I’d buy and one fallen dividend hero I’d sell

G A Chester has contrasting views on these two contrasting stocks.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today, I’m looking at a ‘risky’ emerging growth stock I’d be happy to buy, and at a one-time ‘safe’ dividend stock I’d sell because it looks far too risky.

Multinational, multi-sector prospects

Shares of AIM-listed Optibiotix Health (LSE: OPTI) are trading down about 3% today after a decent run-up in advance of its half-year results, which were released this morning.

With a pipeline of patent-protected products, which modulate the human microbiome to tackle such things as obesity, high cholesterol and diabetes, Optibiotix has stimulated interest from national and multinational companies in both consumer health and pharmaceutical markets. Indeed, it has already penned agreements with, among others, Tata Chemicals, one of India’s leading suppliers of food ingredients and HLH BioPharma Vertriebs, one of Europe’s leading suppliers of probiotics to the pharmacy market.

Commercial take-off

Today’s results for the six months ended 31 May showed revenue of a mere £75,000, compared with cost of sales of £35,000 and administrative expenses of over £1m. Nevertheless, the company reported a statutory profit of £3.2m. This was due to it de-merging and giving a separate AIM listing to its majority-owned skincare subsidiary, Skinbiotherapeutics, leading to an uplift in the value of its investment.

While the income statement showed a profit and the balance sheet a nice increase in net assets, the cash flow statement recorded cash burn of £1.2m. Nevertheless, Optibiotix retains cash of £1.9m, which it says is “sufficient to cover the delivery of existing development and commercial plans.”

With the company targeting a number of “large markets (>£100m) where there are high growth opportunities (CAGR >10%) and a large unmet need” this £54m cap company — at a current share price of 68.5p — could grow rapidly as current and future commercial deals take off. The shares look very buyable to me as a higher-risk-but-potential-very-high-reward proposition.

All not as it seemed

Until recently, many investors viewed support services firm Mitie (LSE: MTO) as a steady growth and reliable dividend stock. Earnings growth had supported annual dividend increases that had taken the payout from 1p a share in 2000 to 12.1p a share last year.

However, all was not as it seemed, with the company increasingly betraying signs of aggressive accounting — and perhaps worse — as I explained when I tagged it The one FTSE 250 stock I’d sell ASAP in May. As this has all begun to unravel, I was expecting some serious ‘kitchen-sinking’ in its annual results on 12 June and a discounted fundraising to shore up the balance sheet at some point, well below the share price of 211p at the time I was writing.

Can of worms

The kitchen-sinking didn’t happen to the extent I expected and, while the dividend was suspended, there’s so far been no fundraising. The shares are currently trading at 267p but I maintain my ‘sell’ stance on the basis of my conviction that there are more worms to come out of the can.

My conviction is only strengthened by Mitie announcing yesterday that the Financial Conduct Authority has launched an investigation into the “timeliness” of its profit warning last September and, more importantly, into “the manner of preparation and content of the company’s financial information, position and results” for its last financial year.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young black man looking at phone while on the London Overground
Value Shares

After a 16% drop, FTSE 100 stock JD Sports Fashion looks like a steal to me

This FTSE 100 stock has tanked since mid-September. Edward Sheldon believes that there's value on offer after the share price…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Is now the time to buy BP shares? Here’s what the charts say

The best time to buy shares in a company is when they’re trading at a discount. But the future is…

Read more »

Investing Articles

Here’s how I’d use £50K to aim for a million when the stock market crashes

Seeing a stock market crash as a buying opportunity could prove lucrative for a well-prepared, long-term investor. Christopher Ruane explains…

Read more »

Stack of one pound coins falling over
Investing Articles

It’s up 27% with a P/E of 9! I’m considering the potential of this blossoming penny stock

Despite several years of losses, this UK penny stock has an impressive valuation. I’m looking to see if it could…

Read more »

US Stock

The Nvidia share price falls! Here’s what I think happens next for the S&P 500

Jon Smith reviews the overnight results from Nvidia and explains why this could stall the S&P 500 performance through to…

Read more »

Investing Articles

Down 15% today, is this FTSE 100 share too cheap for me to miss?

JD Sports' share price has tanked after the FTSE 100 share released another profit warning. Is this the opportunity I've…

Read more »

Investing Articles

Up 8% today, is this FTSE 100 growth stock a slam-dunk buy for me?

Halma's share price is soaring thanks to another headline-grabbing trading update. Is the FTSE 100 stock now too good for…

Read more »

Investing Articles

With a P/E ratio of just 10.5 is now a brilliant time to buy a cut-price FTSE 250 tracker?

Harvey Jones says a recent dip in the FTSE 250 leaves the index trading at bargain levels. One stock in…

Read more »